Re: Inclisiran and other revenues sources
Less than two months ago, Novartis paid nearly $10 billion to acquire The Medicines Company, a deal driven by one asset, an RNAi heart drug called inclisiran. On the first day of JPM, the Swiss pharma announced ambitious plans alongside U.K. health officials to study inclisiran in a wide patient population and to ramp up manufacturing capacity for RNAi medicines.
"I believe inclisiran has the potential to be one of the largest, if not the largest, medicine at Novartis in our history," Novartis CEO Vas Narasimhan said Monday.